Talk:Olaparib
This is the talk page for discussing improvements to the Olaparib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Olaparib.
|
Question
[edit]Does it inhibit just PARP1 or other PARP enzymes ? Rod57 (talk) 11:43, 22 October 2009 (UTC)
Exaggerated coverage
[edit]The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right
Try to keep out some of the more hysterical claims. --Nbauman (talk) 01:56, 23 November 2009 (UTC)
FDA approved yesterday
[edit]An FDA news release announces:
- FDA approves Lynparza to treat advanced ovarian cancer
- First LDT companion diagnostic test also approved to identify appropriate patients
Hope this is useful. --Hordaland (talk) 02:08, 20 December 2014 (UTC)
How many people have taken this?
[edit]It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 (talk • contribs) 15:16, 8 May 2018 (UTC)
Dangling References
[edit]Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.